INTRODUCTION

Cervical cancer is the second most common malignant disease among women worldwide with nearly 80% of cases occurring in less developed countries (1). About 500,000 new cases are diagnosed annually (2). Cervical cancer accounts for the death of 231,000 women annually with over 80% of these deaths occurring in developing countries. In Ghana, a study done over a 52 month period in Korle-Bu Teaching Hospital (KBTH) showed cervical cancer to account for 58.3% of gynaecological cancers (3). Studies in Ivory Coast and Gambia have revealed cervical cancer incidences of 24 and 34%, respectively (4,5). Number of sexual partners, smoking, age of first sexual contact and immunological status have been identified as significant risk factors for development of cervical cancer (6,7). Human papillomaviruses have been identified as the central etiologic agents of cervical cancer (8). It is also clear from several case control and cohort studies that HPV infection is the main factor for the development of cervical intraepithelial neoplasia (CIN) and that risk is significantly increased by persistent infection with high risk HPV genotypes such as types 16 and 18 (9-12). More than 200 types of HPV have been identified using DNA sequence data, out of which 40 different types have been detected in the anogenital area (13). Based on their oncogenic potential, genital HPVs have been divided into high and low risk. High-risk types such as HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66 and 68 are associated...
with high grade CIN and invasive cervical cancer (13). Other genotypes such as HPVs 6, 11, 34, 40, 42, 43 and 44 are classified as low risk types, detected in benign lesions such as condyloma acuminate (14).

Detection of high-risk HPV infections helps to identify women who are at increased risk of development or the progression of a cervical lesion (15, 16). Several HPV targeted therapies and vaccines have been developed, however, it would be better to know the HPV genotypes that are prevalent in each geographical region of the world so that type specific or globally effective vaccines can be produced. A previous study in Ghana showed a 10.7% prevalence of HPV in Ghanaian women attending gynaecological clinics (17). In this present study we determined the prevailing genotypes of HPV present in Ghanaian women with cervical cancer.

**MATERIALS AND METHODS**

*Tissue Materials and Histological Analysis*: Formalin-fixed paraffin embedded blocks of 50 patients with histologically proven cervical cancer obtained from archival specimens of the Pathology Department, Korle-Bu Teaching Hospital, Accra, between January and December 2003 were used in this study. Ethical approval to use the samples was granted according to ethical guidelines established in the University of Ghana Medical School. The first and last sections (5µm) of each tissue were stained with haematoxylin and eosin. These were used as microscopic controls to ensure that the tissue sections used in the PCR contained malignant tissue. To avoid carried-over contamination from one block to another during sectioning, a new disposable microtome knife was used to cut sections from each block.

*Preparation of Genomic DNA*: Genomic DNA was prepared using the method described by Dabic et al. (18) with slight modifications. Briefly, 10µm section was cut from each paraffin block into a 2.0ml microcentrifuge tube. These sections were incubated in 250µl lysis buffer, [1mg/ml Proteinase K (Sigma, USA), in 50mM Tris-HCL pH 8, ImM EDTA, and 0.5% Tween-20 (Sigma, USA)] for 16 hours at 56°C. Proteinase K was inactivated at 100°C for five minutes and the lysate centrifuged at 13000 rpm for five minutes. 0.2-2µl of the supernatant was then used for PCR amplification and the rest of the DNA lysate stored at -20°C until further use.

*HPV Nested Multiplex PCR*: Primer sets (Eurogenetics, Belgium) and the method described by Sotlar et al. (19) was used. The HPV genome was amplified using consensus forward primer (GP-E6-3F) and two consensus back primers (GP-E7-5B and GP-E7-6B). The PCR reaction mix of 50µl contained 10x PCR, buffer (Promega, USA), 2.5mM MgC2, 200µM of each of the four oligonucleotide triphosphates (dNTPs) (Promega, USA), 15pmols of each E6/E7 consensus primer and 1.25 units of Taq Polymerase enzyme (Promega, USA). 0.2-2µl of DNA lysate was used as template for the amplification reaction and sterile double distilled water used to make up the volume to 50µl. The DNA amplification was carried out using a Technne thermal cycler (Promene, Princeton, NJ, USA). The cycling parameters for the first round PCR with the E6/E7 consensus primers were as follows: 94°C for four minutes followed by 40 cycles of 94°C for one minute, 40°C for two minutes, 72°C for two minutes and a single final elongation step of 72°C for ten minutes. For each reaction positive controls (HPV 16 and 18 plasmid DNA) and a negative control (double distilled water) were included. In the second round nested PCR. 1µl of first round PCR product, 15pmols of forward and reverse primers for genotyping were used. The other parameters above remained the same. The genotyping cycling parameters were as follows: 94°C for four minutes followed by 35 cycles of 94°C for 30seconds. 56°C for 30 seconds, 72°C for 45 seconds and a single final elongation step of 72°C for four minutes.

Primers for the identification of high-risk genotypes: 16,18,31,33,35,39,45, 51, 52, 56, 58, 59, 66 and 68 and low-risk genotypes 6/11, 42, 43 and 44 were used. The primers were used in four cocktails each containing four to rive different primer pairs. The PCR products were run on a 2% agarose gel and stained with 0.5µg1ml ethidium bromide to detect the presence of amplified DNA fragments with a hundred base pair DNA molecular weight marker was run along side.

**RESULTS**

The mean age of HPV positive patients was 54.1 years (S.D = 7.6years) ranging from 23 to 80 years. The oldest case was a squamous cell carcinoma and the youngest, an adenocarcinoma (Table 1). All samples were positive for HPV DNA. Forty nine (98%) of the 50 samples could not be typed based on the primers used. In one case a squamous cell carcinoma, we could determine the genotype. Table 2 shows all the HPV genotypes identified, multiple infections were counted more than once. A total of eight different HPV genotypes of the 18 possible genotypes were detected and all were high risk types. One HPV positive sample did not genotype with any of the primers used. HPV 18 was the most prevalent as this was found in 42 (84%) of the 50 samples. The prevalence of other genotypes was as follows: HPV 16 in 12 (24%) samples. HPV 45 in three (6%) samples. HPV 39 in two (4%) samples. and HPV 35,52,56 and 66 in one (2%) sample each.
Table 1
Age Distribution of Types of Cancers in Genotyped Samples

<table>
<thead>
<tr>
<th>Age</th>
<th>SCC</th>
<th>ADC/ASC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-29</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>30-39</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>40-49</td>
<td>10</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>50-59</td>
<td>12</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>60-69</td>
<td>6</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>70-79</td>
<td>6</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>80-89</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>39</td>
<td>10</td>
<td>49</td>
</tr>
</tbody>
</table>

Key:
SCC: Squamous cell carcinoma
ADC: Adenocarcinomas
ASC: Adenosquamous carcinomas

Table 2
HPV Genotypes in Relation to Histologic Types

<table>
<thead>
<tr>
<th>Hpv Genotypes</th>
<th>Squamous cell carcinomas</th>
<th>Adenocarcinomas</th>
<th>Adenosquamous carcinomas</th>
<th>Relative Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV-16</td>
<td>11</td>
<td>1</td>
<td>0</td>
<td>18.8%</td>
</tr>
<tr>
<td>HPV-18</td>
<td>32</td>
<td>7</td>
<td>3</td>
<td>65.6%</td>
</tr>
<tr>
<td>HPV-35</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1.6%</td>
</tr>
<tr>
<td>HPV-39</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>3.1%</td>
</tr>
<tr>
<td>HPV-45</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>4.7%</td>
</tr>
<tr>
<td>HPV-52</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1.6%</td>
</tr>
<tr>
<td>HPV-56</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1.6%</td>
</tr>
<tr>
<td>HPV-66</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1.6%</td>
</tr>
<tr>
<td>HPV-X¹</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

¹Untypable sample based on the 18 primers used for genotyping though positive for HPV DNA

DISCUSSION

The diagnosis of HPV infection in recent times has been based on the detection of viral DNA using PCR assays (10,15). In this work a nested multiplex PCR developed by Sotlar et al. (19) was used in the detection and genotyping of HPV types in paraffin embedded cervical carcinomas in Ghanaian women. Many epidemiological studies indicate that human cancer develops through different molecular biologic pathways. Currently, there is compelling evidence that the development of human cervical cancer without the involvement of specific HPV is exceptional or impossible (15). HPV DNA has been found to be in 46.9 to 100% of archival cervical carcinoma specimens using PCR based methods (16). In this study, HPV DNA prevalence was 98%, which was comparable with other studies (15,16,18). These studies detected HPV in between 65 to 87.6% of patients with invasive cervical cancer in formalin fixed and paraffin-embedded tumour tissues using PCR analysis. To our knowledge, this study is the first genotyping of cervical carcinomas using paraffin embedded specimens in Ghana. A total of 85 studies using PCR to estimate HPV prevalence in invasive cervical cancer in different parts of the world revealed that the common HPV types, in order of decreasing prevalence were 16, 18, 45, 31, 33, 58, 35, 59, 56, 6, 51, 68, 39, 82, 73, 66 and 80 (2). In these studies, for squamous carcinomas (SCC), HPV 16 was the predominant type followed by HPV 18, 45, 31 and 33 in all regions except Asia, where HPV types 58 and 52 were more frequently identified.
Also for adenocarcinoma (ADC) and adenosquamous carcinoma (ASC), HPV prevalence was significantly lower than in SCC and HPV 18 was the predominant type in every region, followed by 16 and 45 (10). The international biological study on cervical cancer also reported HPV 16 as the most prevalent type in 22 countries with the exception of Indonesia, where HPV 18 was the most prevalent type (10). However, in this work the most prevalent HPV type was HPV 18, followed by 16, 45 and 39 respectively.

Data collected from several studies had shown that HPV 31 and 33 were frequently found in cervical carcinomas (10) but these genotypes were absent in the 50 samples we used. This probably supports suggestion that there are different types of HPV causing cancers in different parts of the world. In these samples we genotyped, no low risk HPV types were detected in any of HPV positive samples obtained supporting the fact that only high risk HPVs are integrated into the host cell genome (20). This present study strengthens the argument of causal association between adenocarcinoma / adenosquamous carcinomas and HPV 18 (8). Three cases of HPV 45 were detected which agreed with some clusters of HPV 45 previously found in West Africa (10).

Multiple infections were present in about 12.8% of the cervical cancer samples used in this work. Recent studies also indicated that the presence of multiple HPV infections might contribute to the development or progression of cervical dysplasia (21). The complex interaction of concomitant HPV infections in cervical carcinogenesis remains to be investigated in the future.

In conclusion, this study provides data about the HPV genotypes associated with cervical cancer in Ghanaian women. Eight high-risk HPV genotypes: 16, 18, 35, 39, 45, 52, 56 and 66 were detected and this supported the fact that only high risk HPV’s are integrated into the host cell chromosome in cervical carcinogenesis. HPV type 18 was the most common HPV genotype associated with cervical cancer in Ghanaian women for the samples genotyped.

We believe that this paper provides baseline information on current prevalence of high risk HPV types in cervical cancer in Ghanaian women and this will serve as the basis for comparison of all future studies on the subject.

ACKNOWLEDGEMENTS

To Professor GE Armah and Dr. CA Brown of the Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences, University of Ghana for their immense assistance in the genotyping of the samples and Mr J. Brandful of the Virology Department of NMIMR for the positive control plasmid DNA samples we used in the work. The work was supported in part by a grant from the Ministry of Defence to S. Attoh and financial assistance from the Department of Pathology, University of Ghana Medical School.

REFERENCES


17. Domfeh, A.B. The prevalence of cervico-vaginal papilloma virus in women visiting the gynaecological department of the Korle-Bu Teaching Hospital. MPhil. Thesis, University of Ghana Medical School, Pathology Department; 2003.


